ערך בספרים למניה: OmniAb (OABI)

OmniAb, Inc. (OABI) is developing a therapeutic antibody discovery system, generating long-term revenue by transferring development rights to corporate behemoths. The historical price action of the company's assets is currently at 1.78. The business model relies on providing access to genetically modified animals, allowing the company to collect royalties on drug sales without incurring testing costs. High margins are driven by the uniqueness of the technologies and the absence of operating expenses.

For OmniAb, Inc. (OABI), a global technological partner to the biopharmaceutical sector, this indicator confirms the business's financial viability in creating innovative antibodies. By analyzing the book value per share metric, an investor assesses the remaining net assets after all liabilities are settled, which allows for a judgment on the real dollar protection of capital and the absence of hidden write-downs between quarterly reports.